studies

melanoma (ML), ipilimumab plus SoC vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCA184-024, 2011 0.72 [0.59; 0.87] 0.72[0.59; 0.87]CA184-024, 201110%502NAnot evaluable deaths (OS) (extension)detailed resultsCA184-024, 2011 0.69 [0.57; 0.84] 0.69[0.57; 0.84]CA184-024, 201110%NAnot evaluable progression or deaths (PFS)detailed resultsCA184-024, 2011 0.76 [0.63; 0.92] 0.76[0.63; 0.92]CA184-024, 201110%502NAnot evaluable DCRdetailed resultsCA184-024, 2011 1.15 [0.79; 1.68] 1.15[0.79; 1.68]CA184-024, 201110%502NAnot evaluable objective responses (ORR)detailed resultsCA184-024, 2011 1.56 [0.91; 2.65] 1.56[0.91; 2.65]CA184-024, 201110%502NAnot evaluable AE (any grade)detailed resultsCA184-024, 2011 5.17 [1.48; 18.09] 5.17[1.48; 18.09]CA184-024, 201110%498NAnot evaluable AE (grade 3-4)detailed resultsCA184-024, 2011 3.39 [2.34; 4.94] 3.39[2.34; 4.94]CA184-024, 201110%498NAnot evaluable AE leading to death (grade 5)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable TRAE (any grade)detailed resultsCA184-024, 2011 5.64 [3.80; 8.35] 5.64[3.80; 8.35]CA184-024, 201110%498NAnot evaluable TRAE (grade 3-4)detailed resultsCA184-024, 2011 11.25 [6.30; 20.10] 11.25[6.30; 20.10]CA184-024, 201110%498NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsCA184-024, 2011 10.35 [0.56; 190.49] 10.35[0.56; 190.49]CA184-024, 201110%498NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCA184-024, 2011 21.14 [1.23; 363.94] 21.14[1.23; 363.94]CA184-024, 201110%498NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsCA184-024, 2011 6.16 [0.31; 123.62] 6.16[0.31; 123.62]CA184-024, 201110%498NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsCA184-024, 2011 52.70 [7.19; 385.99] 52.70[7.19; 385.99]CA184-024, 201110%498NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCA184-024, 2011 32.40 [7.79; 134.72] 32.40[7.79; 134.72]CA184-024, 201110%498NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCA184-024, 2011 10.35 [0.56; 190.49] 10.35[0.56; 190.49]CA184-024, 201110%498NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCA184-024, 2011 6.16 [0.31; 123.62] 6.16[0.31; 123.62]CA184-024, 201110%498NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsCA184-024, 2011 0.43 [0.11; 1.68] 0.43[0.11; 1.68]CA184-024, 201110%498NAnot evaluable Asthenia AE (grade 3-4)detailed resultsCA184-024, 2011 0.17 [0.02; 1.39] 0.17[0.02; 1.39]CA184-024, 201110%498NAnot evaluable Chills AE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable Constipation AE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable Cough AE (grade 3-4)detailed resultsCA184-024, 2011 2.04 [0.07; 60.99] 2.04[0.07; 60.99]CA184-024, 201110%498NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsCA184-024, 2011 0.76 [0.17; 3.43] 0.76[0.17; 3.43]CA184-024, 201110%498NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsCA184-024, 2011 21.14 [1.23; 363.94] 21.14[1.23; 363.94]CA184-024, 201110%498NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsCA184-024, 2011 16.77 [0.96; 293.61] 16.77[0.96; 293.61]CA184-024, 201110%498NAnot evaluable Fatigue AE (grade 3-4)detailed resultsCA184-024, 2011 2.44 [1.21; 4.94] 2.44[1.21; 4.94]CA184-024, 201110%498NAnot evaluable Headache AE (grade 3-4)detailed resultsCA184-024, 2011 4.12 [0.46; 37.08] 4.12[0.46; 37.08]CA184-024, 201110%498NAnot evaluable Increase AST AE (grade 3-4)detailed resultsCA184-024, 2011 18.42 [5.64; 60.14] 18.42[5.64; 60.14]CA184-024, 201110%498NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsCA184-024, 2011 34.83 [8.39; 144.67] 34.83[8.39; 144.67]CA184-024, 201110%498NAnot evaluable Nausea AE (grade 3-4)detailed resultsCA184-024, 2011 1.36 [0.30; 6.14] 1.36[0.30; 6.14]CA184-024, 201110%498NAnot evaluable Pruritus AE (grade 3-4)detailed resultsCA184-024, 2011 10.35 [0.56; 190.49] 10.35[0.56; 190.49]CA184-024, 201110%498NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.02; 51.42] 1.02[0.02; 51.42]CA184-024, 201110%498NAnot evaluable Rash AE (grade 3-4)detailed resultsCA184-024, 2011 6.16 [0.31; 123.62] 6.16[0.31; 123.62]CA184-024, 201110%498NAnot evaluable Vomiting AE (grade 3-4)detailed resultsCA184-024, 2011 2.07 [0.61; 6.95] 2.07[0.61; 6.95]CA184-024, 201110%498NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsCA184-024, 2011 1.02 [0.06; 16.34] 1.02[0.06; 16.34]CA184-024, 201110%498NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-05-25 17:25 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 2,283,284,70,235,285,68,127,128,286,69,129 - treatments: 868

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons